| In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilities. | |
| | |
MedLine Citation:
|
PMID: 14576114 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The in vitro activity of garenoxacin (BMS-284756) against 62 clinical Haemophilus influenzae isolates with different fluoroquinolone susceptibilities was determined by the microdilution susceptibility testing method and compared with the activities of other oral quinolones and nonquinolone oral antimicrobial agents. Cefixime presented the highest intrinsic activity (MIC at which 50% of the isolates tested were inhibited [MIC(50)], 0.01 microg/ml), followed by garenoxacin, moxifloxacin, and ciprofloxacin (MIC(50), 0.06 microg/ml), levofloxacin (MIC(50), 0.12 microg/ml), cefuroxime (MIC(50), 1.0 microg/ml), and amoxicillin-clavulanate (MIC(50), 1.0/0.5 microg/ml), amoxicillin (MIC(50), 2 microg/ml), azithromycin (MIC(50), 4 microg/ml), and erythromycin (MIC(50), 8 microg/ml). In strains with ciprofloxacin MICs of < or =0.06 microg/ml, ciprofloxacin and garenoxacin displayed similar MIC(50)s and MIC(90)s, one dilution lower than those of moxifloxacin and levofloxacin. For strains for which ciprofloxacin MICs were > or = 0.12 microg/ml, MIC(50)s were similar for the four quinolones tested, although garenoxacin presented the widest activity range (0.03 to 32 microg/ml) and the highest MIC at which 90% of the isolates tested were inhibited (16.0 microg/ml). For strains without amino acid changes in the quinolone resistance determining region (QRDR) of GyrA and ParC, garenoxacin MICs were < or =0.03 microg/ml; with a single amino acid change in GyrA, garenoxacin MICs were 0.06 to 0.12 microg/ml; with one amino acid change each in GyrA and ParC, garenoxacin MICs were 0.5 to 2.0 micro g/ml; one amino acid change in ParC combined with two amino acid changes in GyrA increased the MICs to > or = 4 microg/ml for all assayed quinolones. We conclude that garenoxacin has excellent activity against H. influenzae, although progressive acquired resistance was observed by step-by-step mutation in the QRDR of gyrA and parC. |
| | |
Authors:
|
María Pérez-Vázquez; Federico Román; Belen Aracil; Rafael Cantón; José Campos |
Related Documents
:
|
15081004 - Betulinic acid and its derivatives as anti-angiogenic agents. 14703354 - Spiculoic acids a and b, new polyketides isolated from the caribbean marine sponge plak... 1376144 - An unusual coloured compound in digests of senile nuclear cataract lens proteins. 17090114 - New polyphenol derivative in ipomoea batatas tubers and its antioxidant activity. 17923394 - Thin self-assembled monolayer for voltammetrically monitoring nicotinic acid in food. 8814304 - Rhizobium fredii synthesizes an array of lipooligosaccharides, including a novel compou... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Antimicrobial agents and chemotherapy Volume: 47 ISSN: 0066-4804 ISO Abbreviation: Antimicrob. Agents Chemother. Publication Date: 2003 Nov |
Date Detail:
|
Created Date: 2003-10-24 Completed Date: 2004-07-06 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 0315061 Medline TA: Antimicrob Agents Chemother Country: United States |
Other Details:
|
Languages: eng Pagination: 3539-41 Citation Subset: IM |
Affiliation:
|
Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda-Madird, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amino Acid Substitution Anti-Infective Agents / pharmacology* DNA Gyrase / genetics DNA Topoisomerase IV / genetics Fluoroquinolones / pharmacology* Haemophilus Infections / microbiology Haemophilus influenzae / drug effects* Humans Microbial Sensitivity Tests Mutation / genetics Quinolones / pharmacology* Reverse Transcriptase Polymerase Chain Reaction |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Infective Agents; 0/Fluoroquinolones; 0/Quinolones; 0/garenoxacin; EC 5.99.1.-/DNA Gyrase; EC 5.99.1.-/DNA Topoisomerase IV |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of triclosan-containing rinse on the dynamics and antimicrobial susceptibility of in vitro p...
Next Document: In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group str...